Credit Suisse’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $4.72M | Sell |
111,634
-62,864
| -36% | -$2.66M | ﹤0.01% | 1324 |
|
|
2023
Q4 | $7.4M | Buy |
174,498
+112,924
| +183% | +$4.79M | 0.01% | 1099 |
|
|
2023
Q3 | $1.34M | Sell |
61,574
-11,199
| -15% | -$244K | ﹤0.01% | 2080 |
|
|
2023
Q2 | $2.31M | Buy |
72,773
+17,304
| +31% | +$550K | ﹤0.01% | 1801 |
|
|
2023
Q1 | $1.35M | Buy |
55,469
+17
| +0% | +$415 | ﹤0.01% | 2106 |
|
|
2022
Q4 | $1.75M | Buy |
55,452
+5,416
| +11% | +$171K | ﹤0.01% | 1948 |
|
|
2022
Q3 | $1.42M | Buy |
50,036
+1,533
| +3% | +$43.4K | ﹤0.01% | 2062 |
|
|
2022
Q2 | $1.28M | Buy |
48,503
+11,622
| +32% | +$307K | ﹤0.01% | 2200 |
|
|
2022
Q1 | $1.29M | Buy |
36,881
+4,920
| +15% | +$172K | ﹤0.01% | 2353 |
|
|
2021
Q4 | $1.04M | Buy |
31,961
+4,464
| +16% | +$145K | ﹤0.01% | 2558 |
|
|
2021
Q3 | $811K | Buy |
27,497
+12,235
| +80% | +$361K | ﹤0.01% | 2712 |
|
|
2021
Q2 | $391K | Buy |
15,262
+2,315
| +18% | +$59.3K | ﹤0.01% | 3159 |
|
|
2021
Q1 | $178K | Buy |
+12,947
| New | +$178K | ﹤0.01% | 3292 |
|